Zenbexus (iberdomide) - BMS
Iberdomide enters multiple myeloma care: A new CELMoD with deep responses but uncertain long-term benefit. (PubMed, Ann Med Surg (Lond)) - Oct 14, 2026 - No abstract available 
Journal • Hematological Malignancies • Multiple Myeloma • Oncology
http://www.ncbi.nlm.nih.gov/pubmed/42866347
 
Ansar Said; Basit Ali Shah; Javed Miandad; Marium Khan; Muhammad Qasim Safi; Nazmun Naher Mouri; Nowshin Jamil Chaity; Sharmin Rumana
 
Oct 14, 2026
 
Prev Next